Asset profile
HRS-5346
Small molecule
Evidence outlook · lead readout
NCT06816264 · Treatment of Lipoprotein Disorder
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT06816264: The trial randomly assigned 120 participants to three HRS-5346 dose groups or placebo and used quadruple masking of participants, care providers, investigators, and outcome assessors. Its primary endpoint was a laboratory measure of lipoprotein(a), rather than a clinical cardiovascular or endoscopic outcome, and the treatment comparison cannot yet be judged because results are not posted.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.
2027 (2)
February 2027 (1)
What to watch
Research analysis
Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.
Sign in to access ResearchOctober 2027 (1)
What to watch
Research analysis
Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.
Sign in to access ResearchAll registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.